Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that Johan Eriksson resigns from the Board of Directors at his own request, effective immediately.
According to Cereno Scientific’s Articles of Association, the Board of Directors shall consist of a minimum of four and a maximum of eight members. Following Johan Eriksson’s resignation, the Board will consist of five members and will therefore continue to comply with the requirements of the Articles of Association.